The North American Research Committee on Multiple Sclerosis (NARCOMS) Registry is a
database that contains information from over 35,000 patient volunteers on symptom severity …

Objective: To create a reference table of disability outcomes in multiple sclerosis (MS) that
would enable patients to rank their disability relative to others' with similar disease duration …

The North American Research Committee on Multiple Sclerosis is a voluntary patient registry
with more than 38,000 registrants as of 2015. In a recent collaborative project, longitudinal …

Objective The objective of this study was to determine the impact of multiple sclerosis (MS)
disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity to …

Objective To compare “hybrid immunity” (prior COVID‐19 infection plus vaccination) and
post‐vaccination immunity to SARS CoV‐2 in MS patients on different disease‐modifying …

OBJECTIVE: To analyze time-trends in age at disability milestones among MS patients who
were enrolled into the MSBase International Registry during 1996–2010 period. METHODS: …

Background Fingolimod is a daily oral medication used to treat relapsing multiple sclerosis (MS).
Clinicians often adopt less frequent dosing for patients with profound drug-induced …

Objective At the time of multiple sclerosis (MS) diagnosis, identifying those at risk for poorer
health-related quality of life and emotional well-being can be a critical consideration for …

Background and Objectives Some patients with multiple sclerosis (MS) receiving ocrelizumab
(OCR) report worsening symptoms toward the end of the 6-month infusion cycle (‘wearing …

Background: The MSBase prediction model of treatment response leverages multiple
demographic and clinical characteristics to estimate hazards of relapses, confirmed disability …